A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors Harboring MET Amplification

Interventions

DRUG: Telisotuzumab Adizutecan

Sponsor

AbbVie